Pfizer Inc
PFE26.430USD
+0.580+2.24%
終値 12/15, 16:00（ET）15分遅れの株価
150.28B時価総額
15.28直近12ヶ月PER
詳細情報 Pfizer Inc 企業名
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Pfizer Incの企業情報
企業コードPFE
会社名Pfizer Inc
上場日Feb 22, 2080
最高経営責任者「CEO」Bourla (Albert)
従業員数81000
証券種類Ordinary Share
決算期末Feb 22
本社所在地66 Hudson Boulevard East
都市NEW YORK
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号10001-2192
電話番号12127332323
ウェブサイトhttps://www.pfizer.com/
企業コードPFE
上場日Feb 22, 2080
最高経営責任者「CEO」Bourla (Albert)
Pfizer Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7800.53%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
他の
7.52B
51.29%
地域別USD
会社名
収益
比率
United States
8.89B
60.70%
Developed Markets
3.39B
23.16%
Emerging Markets
2.37B
16.15%
事業別
地域別
事業別USD
会社名
収益
比率
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
他の
7.52B
51.29%
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
他の
76.30%
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
他の
76.30%
種類
株主統計
比率
Investment Advisor
33.35%
Investment Advisor/Hedge Fund
23.13%
Research Firm
2.99%
Pension Fund
2.47%
Bank and Trust
1.76%
Sovereign Wealth Fund
1.72%
Insurance Company
1.27%
Hedge Fund
0.93%
Holding Company
0.05%
他の
32.34%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
4830
3.80B
66.84%
-140.11M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
530.68M
9.33%
+10.10M
+1.94%
Jun 30, 2025
State Street Investment Management (US)
296.30M
5.21%
-669.22K
-0.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
288.89M
5.08%
-2.65M
-0.91%
Jun 30, 2025
Geode Capital Management, L.L.C.
127.47M
2.24%
+1.82M
+1.45%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
77.00M
1.35%
-26.49M
-25.60%
Jun 30, 2025
State Farm Insurance Companies
57.59M
1.01%
-158.70K
-0.27%
Jun 30, 2025
MFS Investment Management
72.76M
1.28%
-276.04K
-0.38%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
54.65M
0.96%
+4.18M
+8.29%
Jun 30, 2025
BlackRock Investment Management (UK) Ltd.
48.87M
0.86%
+8.45M
+20.91%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Mon, Dec 1
更新時刻: Mon, Dec 1
銘柄名
比率
VanEck Pharmaceutical ETF
10.43%
First Trust NASDAQ Pharmaceuticals ETF
7.73%
Franklin US Dividend Booster Index ETF
7.39%
First Trust Morningstar Dividend Leaders Index Fund
6.54%
WBI Power Factor High Dividend ETF
4.87%
Invesco Pharmaceuticals ETF
4.84%
Coastal Compass 100 ETF
4.8%
iShares U.S. Pharmaceuticals ETF
4.43%
Amplify Weight Loss Drug & Treatment ETF
4.14%
Roundhill GLP-1 & Weight Loss ETF
3.73%
詳細を見る
VanEck Pharmaceutical ETF
比率10.43%
First Trust NASDAQ Pharmaceuticals ETF
比率7.73%
Franklin US Dividend Booster Index ETF
比率7.39%
First Trust Morningstar Dividend Leaders Index Fund
比率6.54%
WBI Power Factor High Dividend ETF
比率4.87%
Invesco Pharmaceuticals ETF
比率4.84%
Coastal Compass 100 ETF
比率4.8%
iShares U.S. Pharmaceuticals ETF
比率4.43%
Amplify Weight Loss Drug & Treatment ETF
比率4.14%
Roundhill GLP-1 & Weight Loss ETF
比率3.73%
配当金
過去5年間の配当金総支払額は
44.91B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Oct 09, 2025
PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025
Nov 07, 2025
Dec 01, 2025
Nov 07, 2025
Jun 25, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025
Jul 25, 2025
Sep 02, 2025
Jul 25, 2025
Apr 23, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025
May 09, 2025
Jun 13, 2025
May 09, 2025
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
詳細を見る
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Pfizer Incの上位5名の株主は誰ですか？
Pfizer Incの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は530.68M株を保有しており、これは全体の9.33%に相当します。
State Street Investment Management (US)は296.30M株を保有しており、これは全体の5.21%に相当します。
BlackRock Institutional Trust Company, N.A.は288.89M株を保有しており、これは全体の5.08%に相当します。
Geode Capital Management, L.L.C.は127.47M株を保有しており、これは全体の2.24%に相当します。
Norges Bank Investment Management (NBIM)は93.65M株を保有しており、これは全体の1.65%に相当します。
The Vanguard Group, Inc.は530.68M株を保有しており、これは全体の9.33%に相当します。
State Street Investment Management (US)は296.30M株を保有しており、これは全体の5.21%に相当します。
BlackRock Institutional Trust Company, N.A.は288.89M株を保有しており、これは全体の5.08%に相当します。
Geode Capital Management, L.L.C.は127.47M株を保有しており、これは全体の2.24%に相当します。
Norges Bank Investment Management (NBIM)は93.65M株を保有しており、これは全体の1.65%に相当します。
Pfizer Incの株主タイプ上位3種は何ですか？
Pfizer Incの株主タイプ上位3種は、
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
Pfizer Inc（PFE）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Pfizer Incの株式を保有している機関は4830社あり、保有株式の総市場価値は約3.80Bで、全体の66.84%を占めています。2025Q2と比較して、機関の持ち株は-0.91%増加しています。
Pfizer Incの最大の収益源は何ですか？
FY2025Q2において、Eliquis alliance revenues and direct sales部門がPfizer Incにとって最大の収益を生み出しており、その金額は2.00Bで、全収益の13.67%を占めています。
